Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Oertli Launches OS 4 Up Dual-Function Cataract-Vitrectomy System
Switzerland-based Oertli announced Feb. 23 that its OS 4 Up dual-function cataract/vitrectomy machine is now available in all CE-certified markets. Features include adaptive energy delivery with Ph...
Ophthalmic Quarterly and 2025 Revenue for Carl Zeiss Meditec, Harrow, RxSight, ANI, and Xbrane
Million Carl Zeiss Meditec reported Feb. 12 that ophthalmology revenue for the last three months of 2025, the first quarter of its fiscal year 2025/2026, totaled €356.9 million ($419.2 million, con...
Rayner Acquires Distribution Rights to Anikavisc OVD in US
UK-based Rayner reported March 2 that it had acquired the US distribution rights to Anikavisc, an ophthalmic viscosurgical device (OVD), from Japan’s Visco Technologies Inc. Anikavisc, a cohesive f...
US FDA Gives Green Light to Phase III Trial of Harrow’s Triesence for Post-op Inflammation and Pain
Nashville, Tennessee-based Harrow reported on March 3 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase III trial of Tri...
Alcon-Lensar Deal Now Expected to Close in First Half of 2026
Alcon’s acquisition of Lensar is now on track to close in the first half of 2026, subject to customary conditions, including receipt of regulatory approval from the US Federal Trade Commission, Len...
US FDA Gives Green Light to Phase I/II Trial of Sanaregen’s Retinal Cell Therapy Candidate
Sanaregen Vision Therapeutics reported March 3 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of its retin...
Sandoz Reports EU Approval for Ranibizumab Biosimilar Branded Ranluspec
Swiss drugmaker Sandoz announced Feb. 23 that the European Commission had granted marketing authorization for Ranluspec, a ranibizumab biosimilar developed by India’s Lupin Limited. Sandoz holds ex...
Cirrus Expands to Singapore, Unveils GA Cell Therapy Candidate
Cirrus Therapeutics reported March 3 that it had established an R&D site in Singapore, expanding its presence in the Asia-Pacific region. The Cambridge, Massachusetts, company also unveiled a secon...
Axol Bioscience Acquires Ophthalmology Business from Newcells Biotech
UK-based Axol Bioscience, a provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, reported Feb. 18 that it had acquired the ophthalmology business of Newcel...
EyeMD Electronic Health Records Platform Rebrands as Optivate
EyeMD EMR Healthcare Systems and its billing subsidiary Abillifeye announced March 3 that they would rebrand as Optivate and launch a new website, optivatehealth.com. Optivate, of Bonita Springs, F...
US FDA Accepts sNDA for Opus’ Presbyopia Candidate, Sets PDUFA Date of Oct. 17, 2026
Commercial partners Viatris and Opus Genetics reported Feb. 25 that the US FDA had accepted the supplemental new drug application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%), targeti...
2025 Ophthalmic Revenue Roundup for Alcon, Apellis, Tarsus, and Immunocore
Alcon reported Feb. 24 that its full year 2025 net sales totaled $10.3 billion, a 5 percent increase over $9.8 billion in 2024. Q4-2025 sales were $2.7 billion, a 9 percent increase over $2.5 billi...
Past News Stories
Children’s Hospital Los Angeles Pioneers Aqueous Biopsy Test for Ocular Cancer
Researchers at Children’s Hospital Los Angeles (CHLA) have developed a liquid biopsy test of aqueous humor that they say can significantly improve the diagnosis and clinical management of tumors in...
G360 Meeting Sets Fundraising Record, Shines Spotlight on Range of Stakeholders
The 2026 Glaucoma 360 meeting set a record for fundraising, with its gala taking in $715 thousand in donations and the New Horizons Forum bringing in another $462 thousand from corporate sponsorshi...
Outlook Grants Mediconsult Rights to Market Lytenava in Switzerland
Outlook Therapeutics announced Feb. 19 an agreement granting Mediconsult exclusive commercial distribution rights for Lytenava (bevacizumab gamma) in the Swiss market. Financial details were not di...
HelpMeSee Launches Simulation-Based MSICS Training Centers in Ghana, Nigeria
Global nonprofit group HelpMeSee announced in February that it had opened new virtual training centers for manual small incision cataract surgery (MSICS) in Ghana and Nigeria. Both training centers...
Formosa Licenses Clobetasol Drops to Arrotex for Australia, New Zealand
Taiwan-based Formosa Pharmaceuticals announced Feb. 23 that it had agreed to license to Arrotex Pharmaceuticals exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inf...
US FDA Gives Green Light to Phase II/III Trial of NexEos Bio’s Vernal Keratoconjunctivitis Candidate
NexEos Bio reported on Feb. 19 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase II/III trial of NTX-1024, a topical can...
US FDA Gives Green Light to Phase II Trial of Cloudbreak’s Presbyopia Drop Candidate
The financial website TipRanks reported on Feb. 15 that the US FDA had signed off on Cloudbreak Pharma’s investigational new drug (IND) application, allowing the company to proceed with a Phase II ...
Surging Economy, Aging Population to Fuel Growth in India’s Ophthalmic Market through 2030
India’s ophthalmic market is poised for strong growth over the next five years. The market will continue to expand across key ophthalmic subspecialties through 2030, according to Market Scope’s for...
Dropless Cataract Surgery Gets a Boost as Interest, Data Align
Dropless cataract surgery continues to gain traction as surgeons seek to simplify postoperative care and im-prove patient adherence—but the meaning and adoption of the practice vary significantly. ...
US FDA Approves Re-administration of Glaukos’ iDose TR
Glaukos announced Jan. 28 that the US FDA had approved a supplement to its new drug application allowing for re-administration of iDose TR, the company’s intracameral travoprost implant for glaucom...
Nidek Launches Phantom Open-Field Refraction System
Japanese company Nidek reported Jan. 26 that it had launched the Phantom Open-Field Refractive System. An open-field system eliminates the traditional phoropter in front of the patient; instead, vi...
Select US FDA Approvals and Clearances in January 2026
The US FDA’s ophthalmic device division granted clearance to one device using the 510(k) pathway in January 2026, according to the agency’s database. Phelcom Technologies received clearance for its...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.